VERTEX PHARMACEUTICALS INC / MA Form 8-K March 09, 2006

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 8, 2006

VERTEX PHARMACEUTICALS INCORPORATED

(Exact name of registrant as specified in its charter)

MASSACHUSETTS 000-19319 04-3039129

04-3039129 3

(State or other jurisdiction of incorporation)

(Commission File Number)


(IRS Employer Identification No.)

130 Waverly Street Cambridge, Massachusetts 02139

(Address of principal executive offices) (Zip Code)

(617) 444-6100

Registrant s telephone number, including area code:



04-3039129 4

Item 8.01. Other Events.

On March 8, 2006, Vertex Pharmaceuticals Incorporated issued a press release that reported results from a Phase II clinical study with VX-702, an investigational oral p38 MAP kinase inhibitor, for the treatment of rheumatoid arthritis. A copy of that press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits

Exhibit

Description of Document

99.1

Press Release of Vertex Pharmaceuticals Incorporated, dated March 8, 2006, titled Vertex Reports Investigational p38MAP Kinase Inhibitor, VX-702, Meets Primary Objectives in Phase II Clinical Study in Rheumatoid Arthritis.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VERTEX PHARMACEUTICALS INCORPORATED

(Registrant)

Date: March 8, 2006

/s/ Ian F. Smith
Ian F. Smith
Executive Vice President and Chief Financial
Officer

2

SIGNATURES 5